{"name":"Virtuoso BINco, Inc.","slug":"virtuoso-binco-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOLXMtZlFJTmRmZVZ4YXA5bEdrVHpwTXMzR1VJallzekU0ZXhmUERqOTctUzh1b3FycmM2Ul9hSDYyUF9lSDZheDh6RTc3ZWF6WXlYaWpSZlFtc01IbFRvX3FLeVVqNzFDZmh1elZwR2F2QmR4RUh4WlJFWEQ1X3dGR3J3bTJ4Q2xkOHZXdVFRbE1rVzU3WktXRlE3T1RJUXQ3UUVmcXJMRUswYlYwRmVhM3JWekUxWWp6RnhTLVA3Rm1NSUJlM2pDclpFbThVMDFrOTFzeWUtaDMtVWFsZkdoMUVyVHpEdTVRakVwbFl6SXMwYjZUS3FRR04xYnNWMEk?oc=5","date":"2025-03-24","type":"pipeline","source":"PR Newswire UK","summary":"CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight - PR Newswire UK","headline":"CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-10-23","type":"trial","source":"PR Newswire","summary":"Anti-CD38 mAb Market to Accelerate Substantially During the Study Period (2020-2034) Owing to a Strong Uptake of DARZALEX in Multiple Myeloma and Expected Entry of anti-CD38 mAbs in Autoimmune Disease","headline":"Anti-CD38 mAb Market to Accelerate Substantially During the Study Period (2020-2034) Owing to a Strong Uptake of DARZALE","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}